Recent News

• 09.29.2025 - KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint
• 09.10.2025 - H.C. Wainwright 27th Annual Global Investment Conference
• 09.08.2025 - Graig Suvannavejh
• 09.03.2025 - KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference
• 09.02.2025 - KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director
• 08.13.2025 - H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
• 08.08.2025 - KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update
• 08.06.2025 - KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
• 07.16.2025 - KPI-012 for Rare Ocular Surface Disease
• 07.16.2025 - Aydin Huseynov

Recent Filings

• 09.29.2025 - 8-K Current report
• 09.29.2025 - EX-99.1 EX-99.1
• 09.18.2025 - 8-K Current report
• 09.11.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 09.11.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 09.02.2025 - 8-K Current report
• 09.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.08.2025 - 8-K Current report
• 08.08.2025 - EX-99.1 EX-99.1
• 08.08.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]